[{"orgOrder":0,"company":"Reyon Pharmaceutical Co., Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Teicoplanin","moa":"||Cell wall peptidoglycan synthesis","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Reyon Pharmaceutical Co., Ltd","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Reyon Pharmaceutical Co., Ltd \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Reyon Pharmaceutical Co., Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Neupharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Teicoplanin","moa":"Cell wall peptidoglycan synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Neupharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Aerosol for Inhalation","sponsorNew":"Neupharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Neupharma \/ Inapplicable"},{"orgOrder":0,"company":"Neupharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Teicoplanin","moa":"Cell wall peptidoglycan synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Neupharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Aerosol for Inhalation","sponsorNew":"Neupharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Neupharma \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals for Teicoplanin A2-5

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
filter

Year

filter

DEALS // DEV.

filter

Country

filter
Sponsor
filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

Therapeutic Area by Lead Product

ForexGraph

Study Phase by Lead Product

ForexGraph

Company by Lead Product

ForexGraph

Top Deals by Deal Size (USD bn)

ForexGraph

01

AAN
Not Confirmed
AAN
Not Confirmed

Details : Neupharma is developing an inhaled formulation of teicoplanin, a glycopeptide antibiotic, for the treatment of methicillin-resistant Staphylococcus aureus infections in patients with cystic fibrosis.

Product Name : Teicoplanin Sandoz

Product Type : Antibiotic

Upfront Cash : Inapplicable

March 18, 2021

Lead Product(s) : Teicoplanin

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Phase I

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

blank

02

AAN
Not Confirmed
AAN
Not Confirmed

Details : Teicoplanin is a glycopeptide antibiotic, which is being evaluated in combination with arbekacin sulfate for the treatment of covid-19.

Product Name : Undisclosed

Product Type : Antibiotic

Upfront Cash : Inapplicable

October 06, 2020

Lead Product(s) : Teicoplanin,Arbekacin Sulfate

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Preclinical

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

blank

03

AAN
Not Confirmed
AAN
Not Confirmed

Details : Neupharma is developing an inhaled formulation of teicoplanin, a glycopeptide antibiotic, for the treatment of methicillin-resistant Staphylococcus aureus infections in patients with cystic fibrosis.

Product Name : Teicoplanin Sandoz

Product Type : Antibiotic

Upfront Cash : Inapplicable

September 28, 2020

Lead Product(s) : Teicoplanin

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Phase I

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

blank